Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Active cancer and ongoing antineoplastic treatments are major factors for severe COVID-19 and death, reasons why the SARS-CoV-2 vaccination remains a priority in cancer patients (CPs). However, immunocompromised patients were excluded from major studies on mRNA vaccines, and could have a decreased response to vaccination, as recently demonstrated in solid organ transplant recipients. Herein, we aimed to assess the proportion of antibody response 4 weeks after the first injection of the BNT162b2 (Pfizer-BioNTech) vaccine in CPs and health care workers (HCWs) as the control population.

Keywords

Cancer SARS-CoV-2 COVID-19 mRNA vaccine Vaccination Serology

Domains

Vaccinology Infectious diseases Emerging diseases Cancer

Fichier principal

Palich et al. - 2021 - Weak immunogenicity after a single dose of SARS-Co.pdf (216.23 Ko)

Origin	Files produced by the author(s)

Gestionnaire HAL 3 Sorbonne Université : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03220233

Submitted on : Friday, May 7, 2021-10:13:06 AM

Last modification on : Thursday, November 7, 2024-2:21:16 PM

Long-term archiving on : Sunday, August 8, 2021-6:19:46 PM

Dates and versions

hal-03220233 , version 1 (07-05-2021)

Identifiers

HAL Id : hal-03220233 , version 1
DOI : 10.1016/j.annonc.2021.04.020

Cite

Romain Palich, M. Veyri, S. Marot, A. Vozy, J. Gligorov, et al.. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Annals of Oncology, In press, ⟨10.1016/j.annonc.2021.04.020⟩. ⟨hal-03220233⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM CNRS IPLESP SORBONNE-UNIVERSITE SU-MEDECINE

44 View

53 Download